CNTNAP2 and cancer: Autoantibodies with an intermediate risk for cancer association comprise N-methyl-d-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), GABA type B receptor (GABABR), metabotropic glutamate receptor 5 (mGluR5), contactin-associated protein-like 2 (CASPR2), and P/Q-type voltage-gated calcium channel (P/Q-type VGCC) [15].